Tokyo, Japan – August 25, 2026 – Neusignal Therapeutics, Inc. (“NTX”) has been selected for “Forbes Asia 100 To Watch 2026” announced by Forbes Asia.
Encouraged by this selection, all of our employees will continue to devote our full efforts to the research and development of therapeutic drugs for Alzheimer’s disease.

Article link (web version): http://www.forbes.com/100towatch
Also available in the September 2026 issue of Forbes Asia Magazine.

■ About Forbes Asia 100 To Watch

“Forbes Asia 100 to Watch” is a Forbes initiative that selects 100 notable small and medium-sized enterprises and startups in the Asia-Pacific region. This year, a total of 16 countries and territories are represented, with 9 companies selected from Japan, and our company was one of them.

Company Overview

・ Established: April 2022
・ Location: 3-11-5 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
・ Representative Director: Itaru Arimoto, Ph.D.
・ Business activities: Research and development of treatments for dementia and psychiatric disorders, exploration of early-stage drug discovery for brain diseases
・ Website: https://neusignal-tx.com/